Meta-analysis of the effectiveness and safety of sulfasalazine in the treatment of ankylosing spondylitis
Jia-cheng ZANG,Jian-xiong MA,Tao WANG,Peng TIAN,Chao HAN,Xin-long MA
DOI: https://doi.org/10.3969/j.issn.1000-1905.2017.06.021
2017-01-01
Abstract:Objective To assess the effectiveness and safety of sulfasalazine in the treatment of ankylosing spondylitis (AS).Methods Randomized trials of SSZ and placebo in treatment of AS were selected.A computer-based online search of Medline,EMBASE,Cochrane CENTRAL (First Quarter 2017),ScienceDirect,OVID,SpringerLink and The China Biological Medicine Database,and manual retrieval of several related journals were used.The included trials were screened out according to the criterion of inclusion and exclusion.The quality of included trials was evaluated.Data were extracted by two reviewers independently.RevMan 5.1.1 was used for data analysis.Results After screening,13 studies were included.A total of 1 110 patients,of which 606 were in group SSZ,and 504 in the placebo group.The results of meta-analysis showed that outstanding relativity and statistically significant difference were found in the following indexes:Spondylitis function index [MD =-0.18,95 ％ CI (-0.23,-0.18),P＜0.00001],VASofback pain[MD=-2.25,95％CI(-4.04,-0.26),P=0.01],duration of morning stiffness [MD =-0.28,95％ CI (-0.35,-0.20),P ＜ 0.00001],Chest expansion[MD =-0.18,95％CI(-0.32,-0.03),P=0.02],and ESR[MD =-3.28,95％CI(-4.60,-1.96),P ＜0.00001].The incidence of side effect in SSZ was higher than placebo group[MD =1.65,95％ CI(1.18,2.3),P =0.003].There was no significant difference in followings:night pain,physical examination of spine and CRP.Conclusion The efficacy of SSZ in the treatment of early,active,peripheral arthritis and high levels of acute inflammatory reaction is significant and the efficacy cost is higher in AS patients.Under the strict laboratory monitoring,complications can be effectively prevented and controlled.